Europe
More than a dozen countries have suspended deployment of the AstraZeneca-Oxford University vaccine after cases of blood clots were reported.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The goal is to “identify concrete and actionable steps to review and update the analysis of pharmaceutical mergers.”
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
France and Germany are two out of more than a dozen countries that suspended deployment of the AstraZeneca-Oxford University vaccine after reports of blood clots were reported.
Topline data from Merck KGaA’s Phase II INTR@PID BTC 047 study show bintrafusp alfa has single-agent efficacy and safety in the second-line treatment of locally advanced or metastatic biliary tract cancer in patients who have either failed or are intolerant to first-line platinum-based chemotherapy.
A study published in the journal Nature suggest the U.K. strain may cause a 61% higher risk of 28-day mortality.
The COVID-19 pandemic is not only an international health crisis, but a burgeoning geopolitical exercise for Russia to win the hearts and minds of a large portion of the world while undermining the West.
Long-term data from Janssen’s Phase III DISCOVER-2a trial show that TREMFYA® (guselkumab), a selective IL-23 inhibitor, lead to skin clearance and joint symptom relief for up to two years in patients with active psoriatic arthritis.
Aron Knickerbocker, former Chief Executive Officer (CEO) of RayzeBio and Five Prime Therapeutics, has taken the helm of Aulos Bioscience, a relatively new biotech company focused on the development of highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies the treatment of solid tumors.
PRESS RELEASES